SVA - Sinovac Biotech Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.50
-0.24 (-3.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.74
Open6.64
Bid4.10 x 1300
Ask6.77 x 900
Day's Range6.44 - 6.73
52 Week Range6.40 - 8.75
Volume28,198
Avg. Volume36,312
Market Cap449.032M
Beta0.17
PE Ratio (TTM)20.00
EPS (TTM)0.32
Earnings DateJun 1, 2017 - Jun 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Sinovac Raises $86.73 Million Through Private Placement Transaction

    BEIJING, July 3, 2018 /PRNewswire/ --Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has completed a private placement of its common shares (a "private investment in public equity," or "PIPE") with private investors Vivo Capital and Advantech Capital. Sinovac will receive gross proceeds of $86.73 million. The proceeds will be used to increase the Company's capabilities in research relating to quality control and to build additional production facilities to support the development and commercialization of sIPV-based combination vaccine and other new vaccine projects.

  • PR Newswire2 months ago

    Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court

    BEIJING, June 26, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has filed a motion for partial summary judgment in Delaware Chancery Court. The motion introduces recently obtained information showing that the Sinobioway Consortium, led by Sinobioway Biomedicine Co., Ltd. ("Sinobioway"), a minority shareholder of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), and a group of Sinovac's shareholders led by 1Globe and OrbiMed (the "Dissident Shareholders") reached an agreement, arrangement or understanding before the Company's annual general meeting held on February 6, 2018 (the "AGM"). Prior to the AGM, the Sinobioway Consortium and the Dissident Shareholders agreed to appear at the AGM to nominate and to vote for new directors controlled by Sinobioway or the Dissident Shareholders.

  • Is Sinovac Biotech Ltd’s (NASDAQ:SVA) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.2 months ago

    Is Sinovac Biotech Ltd’s (NASDAQ:SVA) PE Ratio A Signal To Buy For Investors?

    Sinovac Biotech Ltd (NASDAQ:SVA) trades with a trailing P/E of 18.8x, which is lower than the industry average of 27.5x. While this makes SVA appear like a great stock toRead More...

  • PR Newswire2 months ago

    Sinovac Biotech Relaunches Company Website

    BEIJING , June 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:  SVA ) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced ...

  • PR Newswire3 months ago

    Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results

    BEIJING , May 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today that ...

  • PR Newswire3 months ago

    Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing

    BEIJING, May 8, 2018 /PRNewswire/ --  Sinovac Biotech Ltd. (SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has been forced to suspend production at its plant for hepatitis A vaccine, and to destroy the bulk of its hepatitis A vaccines being produced at its Shangdi site, which is capable of producing approximately 3.5 million doses of finished product hepatitis A vaccines. The Company is not presently able to assess the impact on its sales of hepatitis A vaccine due to a lack of certainty regarding both the market's reaction to this incident, as well as the schedule for resuming production. Sinovac made this decision due to actions taken by Aihua Pan, the Chairman of the Board of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), who was appointed by Sinobioway Biomedicine Co., Ltd. ("Sinobioway"), the minority shareholder of Sinovac Beijing.

  • PR Newswire4 months ago

    Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing

    BEIJING , May 1, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China , today announced it ...

  • PR Newswire4 months ago

    Sinovac Forced to Plan to Destroy Bacterial Seeds intended for Pneumo Vaccine Production and Postpone Site Inspection

    BEIJING, April 30, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has been forced to destroy the bacterial seeds intended for use in the production of its 23-valent pneumococcal polysaccharide vaccine, or PPV, and to suspend all preparations for and ultimately postpone the China Food and Drug Administration (CFDA) inspection of the manufacturing site necessary for 23-valent PPV production approval. As previously announced, on April 17, 2018, Mr. Pan and dozens of unnamed individuals forcibly entered Sinovac Beijing's corporate offices and limited the physical movement of the employees in Sinovac Beijing's general manager's office and finance department.

  • PR Newswire4 months ago

    Sinovac Temporarily Blocks Access to Its Websites

    BEIJING , April 30, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire4 months ago

    Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing

    BEIJING , April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire4 months ago

    Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction

    BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (SVA), a leading provider of biopharmaceutical products in China, today announced that on April 26, 2018, it entered into Amendment No. 2 to the Amalgamation Agreement (the "Amendment") to further amend the Amalgamation Agreement, dated as of June 26, 2017 (as amended by Amendment No. 1 to the Amalgamation Agreement, dated as of March 26, 2018, the "Amalgamation Agreement"), among the Company, Sinovac (Cayman) Limited ("Parent") and Sinovac Amalgamation Sub Limited ("Amalgamation Sub"), a wholly-owned subsidiary of Parent. Under the terms of the Amalgamation Agreement, the Amalgamation Agreement may be terminated by the Company or Parent if the amalgamation of Amalgamation Sub with and into the Company (the "Amalgamation") has not occurred on or before April 26, 2018 (the "Termination Date"). The Amendment extends the Termination Date to May 26, 2018.

  • PR Newswire4 months ago

    Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department

    BEIJING , April 23, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire4 months ago

    Sinovac Announces Preliminary Results of Phase III Trial on sIPV

    BEIJING, April 19, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Biotech Co., Ltd. ("Sinovac Beijing") on the unblinding conference held on April 19, 2018. The preliminary results of the trial after unblinding show the seroconversion rate of poliovirus type II is superior to the control vaccine and seroconversion rates of the other two types of poliovirus are non-inferior to the control vaccine.

  • PR Newswire4 months ago

    Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd.

    - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Company and ...

  • 10 Bulletproof Blue-Chip Growth Stocks to Invest In
    InvestorPlace4 months ago

    10 Bulletproof Blue-Chip Growth Stocks to Invest In

    While traditional blue-chip stocks are good choices for the volatility in the market, another good strategy is to grab some blue-chip growth stocks to take advantage of the upside move. Bear in mind, these are small- to mid-cap stocks, so don’t chase them. Lumentum Holdings Inc (NASDAQ:LITE) is one of the biggest-cap stocks in this list, with a $4 billion market cap.

  • 10 Healthcare Stocks to Stave Off the Market Flu
    InvestorPlace4 months ago

    10 Healthcare Stocks to Stave Off the Market Flu

    While the markets run up and down because tech stocks are doing one thing or another, or retailers struggle to improve same-store sales, there isn’t much debate about the future of the healthcare sector.Source: Shutterstock

  • Why Sinovac Biotech Ltd’s (NASDAQ:SVA) ROE Of 18.01% Does Not Tell The Whole Story
    Simply Wall St.5 months ago

    Why Sinovac Biotech Ltd’s (NASDAQ:SVA) ROE Of 18.01% Does Not Tell The Whole Story

    Sinovac Biotech Ltd (NASDAQ:SVA) generated a below-average return on equity of 18.01% in the past 12 months, while its industry returned 18.11%. An investor may attribute an inferior ROE toRead More...

  • PR Newswire5 months ago

    Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction

    BEIJING, March 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (SVA), a leading provider of biopharmaceutical products in China, today announced that on March 26, 2018, it entered into Amendment No. 1 to the Amalgamation Agreement (the "Amendment") to amend the Amalgamation Agreement, dated as of June 26, 2017 (the "Amalgamation Agreement"), among the Company, Sinovac (Cayman) Limited ("Parent") and Sinovac Amalgamation Sub Limited ("Amalgamation Sub"), a wholly-owned subsidiary of Parent. Under the terms of the Amalgamation Agreement, the Amalgamation Agreement may be terminated by the Company or Parent if the amalgamation of Amalgamation Sub with and into the Company (the "Amalgamation") has not occurred on or before March 26, 2018 (the "Termination Date"). The Amendment extends the Termination Date to April 26, 2018.

  • PR Newswire5 months ago

    Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties

    BEIJING, March 15, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (SVA), a leading provider of biopharmaceutical products in China, today responded to public statements made by other parties falsely claiming to control the Company, including a press release falsely purporting to come from Sinovac itself. The Company emphasized that third parties, including the dissident shareholders who sought to disrupt the election of directors at the AGM  do not have the authority to determine or announce the results of Sinovac's AGM, comment on the Company's governance or speak on behalf of the Company.

  • What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like?
    Simply Wall St.5 months ago

    What Does Sinovac Biotech Ltd’s (NASDAQ:SVA) Ownership Structure Look Like?

    I am going to take a deep dive into Sinovac Biotech Ltd’s (NASDAQ:SVA) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • PR Newswire5 months ago

    Sinovac Amends Shareholder Rights Plan

    BEIJING , March 6, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China , today announced ...

  • PR Newswire5 months ago

    Sinovac Announces Enhancement of Corporate Governance and Management of China Operating Entity

    BEIJING , March 5, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today ...

  • PR Newswire5 months ago

    Sinovac Announces Re-Election of All Directors at Annual General Meeting

    BEIJING, March 5, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced several important developments, including the re-election of its incumbent directors at its Annual General Meeting of Shareholders (AGM), which was held on February 6, 2018, and the filing of legal actions in the Delaware Court of Chancery and in the United States District Court for Massachusetts related to actions taken by certain dissident shareholders.

  • PR Newswire6 months ago

    Sinovac Provides Update on Going Private Transaction

    BEIJING, Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that, in connection with its previously announced going private transaction, the Company has filed a going-private transaction statement on Schedule 13E-3 (as amended, the "Going-Private Statement") with the United States Securities and Exchange Commission (the "SEC"). Attached as an exhibit to the Going-Private Statement is a preliminary proxy statement (the "Preliminary Proxy Statement"). The Company expects to file an amended Going-Private Statement, including a definitive proxy statement (which will be substantially in the same form as the Preliminary Proxy Statement and used in connection with a special meeting of shareholders) as an exhibit, with the SEC in due course.

  • PR Newswire6 months ago

    Sinovac Holds 2017 Annual General Meeting of Shareholders

    BEIJING , Feb. 7, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China , announced today that ...